In the News: New Drug Updates and Notes on the Environment

IV infusionReports from the frontlines of myeloma drug development have been in the news lately. Here is a look at the latest developments:

ODAC Votes Against Accelerated Approval for Selinexor

In an emotional discussion on Tuesday, February 26 at the FDA’s Oncologic Drugs Advisory Committee (ODAC) meeting, committee members voted 8 to 5 to await the results of an ongoing randomized trial (BOSTON phase III trial) comparing bortezomib and dexamethasone with and without selinexor, instead of approving selinexor now based on the single-arm STORM trial results of selinexor plus dexamethasone.

Black Swan Project Tracking Early Disease

In this week’s Myeloma Minute, a new video gives an overview of the IMF Black Swan Research Initiative (BSRI). As we move into 2019, there are ambitious plans to accelerate the search for a cure, uncover the mysteries surrounding early disease onset, and focus on potential prevention strategies.

Understanding immune monitoring, and why global obesity is on the rise

Ever since the IMF launched the Black Swan Research Initiative (BSRI) in 2012 to find the pathway to a cure for multiple myeloma, the project has focused on achieving and documenting minimal residual disease (MRD), the lowest level of disease possible with currently available therapies. However, with both early disease (monoclonal gammopathy of undetermined significance, MGUS, and smoldering multiple myeloma, SMM) and after therapy, many patients can do well even with obvious residual disease. As the BSRI team is learning, MRD assessment is but one step to understanding how myeloma progresses. We can gain even further insight by examining the role of immune cells, the key factor in controlling residual disease.